Madrigal Pharmaceuticals, Inc.(MDGL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MDGL Madrigal Pharmaceuticals, Inc.

未开盘 09-30 16:00:00 EDT

503.96

-5.48

-1.08%

盘后503.96

+0.000.00%

19:30 EDT

最高515.00	最低501.81	成交量26.25万
今开513.10	昨收509.44	日振幅2.59%
总市值116.19亿	流通市值69.17亿	总股本2,306万
成交额1.33亿	换手率1.91%	流通股本1,373万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MDGL","market":"US","secType":"STK","nameCN":"Madrigal Pharmaceuticals, Inc.","latestPrice":503.96,"timestamp":1790798400000,"preClose":509.44,"halted":0,"volume":262462,"hourTrading":{"tag":"盘后","latestPrice":503.96,"preClose":503.96,"latestTime":"19:30 EDT","volume":3574,"amount":1801153.04,"timestamp":1790811002116,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01075690954773873,"floatShares":13725000,"shares":23055522,"eps":-14.216436,"marketStatus":"未开盘","change":-5.48,"latestTime":"09-30 16:00:00 EDT","open":513.1,"high":515,"low":501.81,"amount":133055331.36808,"amplitude":0.025891,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-14.216436,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1790841600000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":509.44,"preHourTrading":{"tag":"盘前","latestPrice":513.87,"preClose":509.44,"latestTime":"09:29 EDT","volume":55,"amount":28271.064250000003,"timestamp":1790774999999,"change":4.43,"changeRate":0.008696,"amplitude":0.006144},"postHourTrading":{"tag":"盘后","latestPrice":503.96,"preClose":503.96,"latestTime":"19:30 EDT","volume":3574,"amount":1801153.04,"timestamp":1790811002116,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.061138,"impliedVol":0.5116,"impliedVolPercentile":0.3785},"requestUrl":"/m/hq/s/MDGL","defaultTab":"news","newsList":[{"id":"1139124982","title":"异动解读｜Madrigal Pharmaceuticals盘中上涨5.08%，报538.145美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1139124982","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139124982?lang=zh_cn&edition=full","pubTime":"2026-08-27 03:00","pubTimestamp":1787770856,"startTime":"0","endTime":"0","summary":"8月27日，Madrigal Pharmaceuticals盘中上涨5.08%，报538.145美元/股，成交额1.23亿美元。Madrigal Pharmaceuticals所在的生物科技行业中，个股中，Moderna跌7.65%，Revolution Medicines跌0.05%，安进跌0.21%，艾伯维公司跌1.61%，吉利德科学跌0.02%。Madrigal Pharmaceuticals是一家生物制药公司，专注于为代谢功能障碍相关脂肪性肝炎提供新的治疗方法。公司核心产品Rezdiffra是一种每日一次的口服肝脏导向甲状腺激素受体β激动剂，旨在针对MASH的关键潜在原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166097486","title":"Madrigal任命John C. Reed博士加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1166097486","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166097486?lang=zh_cn&edition=full","pubTime":"2026-08-12 20:03","pubTimestamp":1786536220,"startTime":"0","endTime":"0","summary":"康舍霍肯，宾夕法尼亚州，2026年8月12日——专注于代谢功能障碍相关脂肪性肝炎新型疗法开发的生物制药公司Madrigal Pharmaceuticals, Inc.今日宣布，已任命John C. Reed医学博士、哲学博士为其董事会成员。Reed博士目前担任强生公司创新医学研发执行副总裁，并是J&J执行委员会成员。Madrigal董事会主席Julian Baker表示：\"非常欢迎John Reed加入Madrigal。Madrigal首席执行官Bill Sibold补充道：\"John的任命体现了Madrigal对科学卓越和长期创新的持续承诺。Madrigal Pharmaceuticals、Rezdiffra及相关标识均为Madrigal Pharmaceuticals, Inc.的商标。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL","BK4588","R","BK4232","BK4585","BK4139","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130029630","title":"异动解读｜Madrigal Pharmaceuticals盘中下跌5.07%，Q2财报亏损同比扩大引发持续抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1130029630","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130029630?lang=zh_cn&edition=full","pubTime":"2026-07-31 22:09","pubTimestamp":1785506944,"startTime":"0","endTime":"0","summary":"7月31日，Madrigal Pharmaceuticals盘中下跌5.07%，报468.38美元/股，成交额8439.04万美元，延续前一交易日跌势。消息面上，公司于前日盘前公布第二季度财报。核心产品Rezdiffra净销售额同比增长71%，在用患者超4.9万人，较去年同期翻倍以上。然而，每股亏损较去年同期的1.90美元扩大4.74%，净亏损达5793.9万美元，盈利能力边际恶化引发市场对盈亏改善节奏的分歧，抛压从前日延续至今。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137818366","title":"异动解读｜Madrigal Pharmaceuticals盘中下跌12.78%，Q2营收超预期但亏损同比扩大引发抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1137818366","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137818366?lang=zh_cn&edition=full","pubTime":"2026-07-30 23:08","pubTimestamp":1785424114,"startTime":"0","endTime":"0","summary":"7月30日，Madrigal Pharmaceuticals盘中下跌12.78%，报476.985美元/股，成交额3.47亿美元。消息面上，公司于盘前公布第二季度财报。数据显示，Q2产品收入3.64亿美元，超出市场预期的3.53亿美元；每股亏损1.99美元，优于分析师一致预期的2.50美元。核心产品Rezdiffra净销售额同比增长71%，在用患者超4.9万人，较去年同期翻倍以上。然而，每股亏损较去年同期的1.90美元扩大4.74%，净亏损达5793.9万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191600164","title":"异动解读 | Madrigal Pharmaceuticals盘中大跌7.56%，Q2财报亏损扩大引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1191600164","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191600164?lang=zh_cn&edition=full","pubTime":"2026-07-30 21:35","pubTimestamp":1785418545,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals (MDGL) 今日盘中大跌7.56%，引发市场广泛关注。消息面上，公司于盘前公布了2026年第二季度财报。尽管当季产品收入达到3.64亿美元，超出市场预期的3.53亿美元，且核心产品Rezdiffra净销售额同比增长71%，但每股亏损1.99美元，较去年同期的1.90美元有所扩大，净亏损达5793.9万美元。营收与患者数量的强劲增长未能掩盖盈利能力边际恶化的隐忧，市场对盈亏改善节奏的分歧导致股价承压。此前富国银行给予Madrigal跑赢大盘评级，目标价685美元，但短期内亏损扩大使投资者趋于谨慎，盘前跌势延续至盘中。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117144817","title":"异动解读 | Madrigal Pharmaceuticals盘前大跌6.14%，Q2财报超预期但每股亏损同比扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=1117144817","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117144817?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:20","pubTimestamp":1785414022,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals今日盘前股价大跌6.14%，引发市场关注。消息面上，公司于盘前公布了2026年第二季度财务报告。数据显示，Q2产品收入达3.64亿美元，超出市场预期的3.53亿美元；每股亏损1.99美元，优于分析师一致预期的2.50美元亏损。核心产品Rezdiffra二季度净销售额3.643亿美元，同比增长71%，截至6月30日在用患者超4.9万人，较去年同期翻倍以上。尽管营收和每股亏损均超预期，但公司每股亏损较去年同期的1.90美元扩大4.74%，净亏损达5793.9万美元。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112230036","title":"异动解读｜Madrigal Pharmaceuticals盘前下跌6.74%，Q2财报超预期但每股亏损同比扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=1112230036","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112230036?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:19","pubTimestamp":1785413947,"startTime":"0","endTime":"0","summary":"7月30日，Madrigal Pharmaceuticals盘前下跌6.74%，报508.12美元/股，成交额75.48万美元。消息面上，公司于当日盘前公布第二季度财报。核心产品Rezdiffra二季度净销售额3.643亿美元，同比增长71%，截至6月30日在用患者超4.9万人，较去年同期翻倍以上。Madrigal Pharmaceuticals是一家生物制药公司，专注于代谢功能障碍相关脂肪性肝炎新疗法，其药物Rezdiffra为每日一次口服肝脏导向甲状腺激素受体β激动剂。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171757303","title":"Madrigal Pharmaceuticals第二季度产品收入达3.64252亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171757303","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171757303?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:21","pubTimestamp":1785410497,"startTime":"0","endTime":"0","summary":"7月30日，Madrigal Pharmaceuticals（股票代码：MDGL）公布了第二季度财报数据。公司本季度产品收入高达3.64252亿美元。然而，净收入方面则表现不佳，录得亏损5793.9万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119297977","title":"Madrigal Pharmaceuticals发布2026年第二季度财报及业务进展更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1119297977","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119297977?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:02","pubTimestamp":1785409338,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals（股票代码：MDGL）近日公布了2026年第二季度的财务业绩，并同步披露了公司最新的业务发展动态。这一季度，公司不仅展示了财务表现，还就关键项目的推进情况进行了说明。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190268389","title":"财报前瞻｜Madrigal Pharmaceuticals, Inc.本季度营收预计达3.53亿美元，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1190268389","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190268389?lang=zh_cn&edition=full","pubTime":"2026-07-23 13:08","pubTimestamp":1784783318,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals, Inc.将于2026年07月30日发布新一季财报，市场关注营收兑现与盈利修复节奏。市场一致预期本季度Madrigal Pharmaceuticals, Inc.营收为3.53亿美元，同比增长117.17%；毛利率预测暂无一致口径；净利润或净利率预测暂无一致口径；调整后每股收益预计为-2.60美元，同比增长28.45%。上季度Madrigal Pharmaceuticals, Inc.营收为3.11亿美元，同比增长126.84%；毛利率为91.38%，同比数据未披露；归属于母公司股东的净利润为-9,439.10万美元，净利率为-30.32%，同比数据未披露；调整后每股收益为-3.25美元，同比增长2.11%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Madrigal Pharmaceuticals, Inc.本季度营收预计达3.53亿美元，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147300726","title":"Madrigal公布数据：Rezdiffra在MASH患者中降低心血管及肝脏相关风险标志物","url":"https://stock-news.laohu8.com/highlight/detail?id=1147300726","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147300726?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:00","pubTimestamp":1779883246,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals公布的最新研究数据显示，其药物Rezdiffra在治疗代谢功能障碍相关脂肪性肝炎（MASH）患者时，能够有效降低与心血管疾病及肝脏损伤相关的风险标志物水平。这一发现进一步支持了Rezdiffra在改善MASH患者长期健康结局方面的潜在价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDGL","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111379185","title":"异动解读 | Madrigal制药宣布Ervogastat/Resmetirom药物相互作用研究进展，股价盘前大涨7.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111379185","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111379185?lang=zh_cn&edition=full","pubTime":"2026-05-06 22:05","pubTimestamp":1778076344,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals, Inc.（MDGL）今日盘前股价大涨7.44%，引起了市场的广泛关注。消息面上，公司宣布其针对Ervogastat/Resmetirom的药物相互作用研究正稳步推进，预计将于2026年第四季度正式启动。这项研究旨在评估该联合疗法在临床应用中可能产生的相互作用，为后续开发提供关键数据支持，增强了市场对公司研发进展和未来前景的信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182779005","title":"Madrigal制药公司：Ervogastat/Resmetirom药物相互作用研究按计划将于2026年第四季度启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1182779005","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182779005?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:03","pubTimestamp":1778065433,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals, Inc.宣布，其针对Ervogastat/Resmetirom的药物相互作用研究正稳步推进，预计将于2026年第四季度正式启动。这项研究旨在评估该联合疗法在临床应用中可能产生的相互作用，为后续开发提供关键数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164904930","title":"财报前瞻｜Madrigal Pharmaceuticals, Inc.本季度营收预计增160.32%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1164904930","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164904930?lang=zh_cn&edition=full","pubTime":"2026-04-29 11:11","pubTimestamp":1777432293,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals, Inc.将于2026年05月06日发布2026年第一季度财报，市场聚焦收入放量与亏损收窄节奏及商业化质量。主营业务亮点：公司收入结构以“产品”业务为核心，上季度实现营收3.21亿美元，同比增长210.77%。一致预期显示本季度营收为2.96亿美元，同比增160.32%，指向处方数量与可及性继续提升。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Madrigal Pharmaceuticals, Inc.本季度营收预计增160.32%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517118936","title":"Madrigal Pharmaceuticals, Inc.盘中异动 临近收盘急速跳水5.01%报329.89美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517118936","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517118936?lang=zh_cn&edition=full","pubTime":"2025-03-07 04:58","pubTimestamp":1741294732,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日04时58分，Madrigal Pharmaceuticals, Inc.股票出现异动，股价大幅下跌5.01%。截至发稿，该股报329.89美元/股，成交量23.1556万股，换手率1.05%，振幅5.68%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.08%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc 是一家生物制药公司，专注于提供代谢功能障碍相关脂肪性肝炎  的新型疗法，这是一种严重的肝病，具有高度未满足的医疗需求，可能导致肝硬化、肝功能衰竭和过早死亡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307045853a262ecd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307045853a262ecd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","BK4139","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517946676","title":"Madrigal Pharmaceuticals, Inc.盘中异动 早盘大幅拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517946676","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517946676?lang=zh_cn&edition=full","pubTime":"2025-03-05 23:45","pubTimestamp":1741189531,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日23时45分，Madrigal Pharmaceuticals, Inc.股票出现波动，股价快速拉升5.02%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.38%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc 是一家生物制药公司，专注于提供代谢功能障碍相关脂肪性肝炎  的新型疗法，这是一种严重的肝病，具有高度未满足的医疗需求，可能导致肝硬化、肝功能衰竭和过早死亡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305234531a260dd65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305234531a260dd65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4139","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516603054","title":"Madrigal Pharmaceuticals, Inc.跌4.30% 股价跌破300美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2516603054","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516603054?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:18","pubTimestamp":1741101533,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时18分，Madrigal Pharmaceuticals, Inc.股票出现波动，股价急速跳水4.30%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.45%。其相关个股中，Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Nutriband Inc C/Wts 涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1171.70%、1133.53%、680.05%，振幅较大的相关个股有Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Celularity Inc C/Wts 16/07/2026 、Protagenic Therapeutics Inc C/Wts 29/04/2026 ，振幅分别为66.03%、66.02%、64.44%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304231853abe7fdc0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304231853abe7fdc0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","MDGL","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516634270","title":"Madrigal Pharmaceuticals, Inc.盘中异动 急速下挫5.35%报323.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634270","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516634270?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:48","pubTimestamp":1741013289,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时48分，Madrigal Pharmaceuticals, Inc.股票出现波动，股价大幅下挫5.35%。截至发稿，该股报323.02美元/股，成交量3.3061万股，换手率0.15%，振幅3.05%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.10%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Geovax Labs, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为368.92%、109.98%、69.27%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Geovax Labs Inc C/Wts 29/09/2025，振幅分别为140.46%、68.30%、24.83%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224810989a1449&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224810989a1449&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4139","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516548069","title":"Madrigal Pharmaceuticals, Inc.2024财年实现净利润-4.66亿美元，同比减少24.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516548069","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516548069?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:00","pubTimestamp":1740931237,"startTime":"0","endTime":"0","summary":"3月3日，Madrigal Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-4.66亿美元，同比减少24.60%；其中营业收入为1.80亿美元，每股基本收益为-21.90美元。从资产负债表来看，Madrigal Pharmaceuticals, Inc.总负债2.88亿美元，其中短期债务983000.00美元，资产负债比为3.62，流动比率为6.12。机构评级：截至2025年3月3日，当前有16家机构对Madrigal Pharmaceuticals, Inc.目标价做出预测，其中目标均价为411.31美元，其中最低目标价为239.00美元，最高目标价为544.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000057abe4aca4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000057abe4aca4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514332004","title":"Madrigal Pharmaceuticals, Inc.盘中异动 股价大跌5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514332004","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514332004?lang=zh_cn&edition=full","pubTime":"2025-02-28 04:43","pubTimestamp":1740688985,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日04时43分，Madrigal Pharmaceuticals, Inc.股票出现波动，股价急速跳水5.18%。Madrigal Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.48%。其相关个股中，Pepgen Inc.、Ibio, Inc.、Cingulate Inc C/Wts 10/12/2026 涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Vincerx Pharma, Inc.较为活跃，换手率分别为1943.02%、410.26%、197.12%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pepgen Inc.、Pds Biotechnology Corporation，振幅分别为86.14%、67.32%、55.84%。Madrigal Pharmaceuticals, Inc.公司简介：Madrigal Pharmaceuticals Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228044306abdfbfc0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228044306abdfbfc0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","MDGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.madrigalpharma.com","stockEarnings":[{"period":"1week","weight":-0.0177},{"period":"1month","weight":-0.0668},{"period":"3month","weight":-0.0457},{"period":"6month","weight":-0.0785},{"period":"1year","weight":0.0988},{"period":"ytd","weight":-0.1346}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Madrigal Pharmaceuticals, Inc.于2000年3月成立并在2001年7月开始运营。该公司是一家生物制药公司，专注于为代谢功能障碍相关脂肪性肝炎提供新的治疗方法。脂肪性肝炎是一种严重的肝病，其医疗需求高度未得到满足，可导致肝硬化、肝衰竭、癌症、肝移植需求和过早死亡。该公司的药物Rezifra是一种每日一次的口服肝脏导向甲状腺激素受体β激动剂，旨在针对MASH的关键潜在原因。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.018335},{"month":2,"riseRate":0.7,"avgChangeRate":0.060749},{"month":3,"riseRate":0.3,"avgChangeRate":-0.012858},{"month":4,"riseRate":0.5,"avgChangeRate":0.006598},{"month":5,"riseRate":0.3,"avgChangeRate":0.113604},{"month":6,"riseRate":0.7,"avgChangeRate":0.037265},{"month":7,"riseRate":0.1,"avgChangeRate":-0.084013},{"month":8,"riseRate":0.636364,"avgChangeRate":0.102406},{"month":9,"riseRate":0.363636,"avgChangeRate":0.10692},{"month":10,"riseRate":0.6,"avgChangeRate":0.054686},{"month":11,"riseRate":0.6,"avgChangeRate":0.099039},{"month":12,"riseRate":0.4,"avgChangeRate":0.372201}],"exchange":"NASDAQ","name":"Madrigal Pharmaceuticals, Inc.","nameEN":"Madrigal Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Madrigal Pharmaceuticals, Inc.(MDGL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Madrigal Pharmaceuticals, Inc.(MDGL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Madrigal Pharmaceuticals, Inc.,MDGL,Madrigal Pharmaceuticals, Inc.股票,Madrigal Pharmaceuticals, Inc.股票老虎,Madrigal Pharmaceuticals, Inc.股票老虎国际,Madrigal Pharmaceuticals, Inc.行情,Madrigal Pharmaceuticals, Inc.股票行情,Madrigal Pharmaceuticals, Inc.股价,Madrigal Pharmaceuticals, Inc.股市,Madrigal Pharmaceuticals, Inc.股票价格,Madrigal Pharmaceuticals, Inc.股票交易,Madrigal Pharmaceuticals, Inc.股票购买,Madrigal Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Madrigal Pharmaceuticals, Inc.(MDGL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Madrigal Pharmaceuticals, Inc.(MDGL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}